Structural Robustness of the Gut Mucosal Microbiota Is Associated
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio In
microorganisms Review The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease Spase Stojanov 1,2, Aleš Berlec 1,2 and Borut Štrukelj 1,2,* 1 Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia; [email protected] (S.S.); [email protected] (A.B.) 2 Department of Biotechnology, Jožef Stefan Institute, SI-1000 Ljubljana, Slovenia * Correspondence: borut.strukelj@ffa.uni-lj.si Received: 16 September 2020; Accepted: 31 October 2020; Published: 1 November 2020 Abstract: The two most important bacterial phyla in the gastrointestinal tract, Firmicutes and Bacteroidetes, have gained much attention in recent years. The Firmicutes/Bacteroidetes (F/B) ratio is widely accepted to have an important influence in maintaining normal intestinal homeostasis. Increased or decreased F/B ratio is regarded as dysbiosis, whereby the former is usually observed with obesity, and the latter with inflammatory bowel disease (IBD). Probiotics as live microorganisms can confer health benefits to the host when administered in adequate amounts. There is considerable evidence of their nutritional and immunosuppressive properties including reports that elucidate the association of probiotics with the F/B ratio, obesity, and IBD. Orally administered probiotics can contribute to the restoration of dysbiotic microbiota and to the prevention of obesity or IBD. However, as the effects of different probiotics on the F/B ratio differ, selecting the appropriate species or mixture is crucial. The most commonly tested probiotics for modifying the F/B ratio and treating obesity and IBD are from the genus Lactobacillus. In this paper, we review the effects of probiotics on the F/B ratio that lead to weight loss or immunosuppression. -
Gut Microbiota and Inflammation
Nutrients 2011, 3, 637-682; doi:10.3390/nu3060637 OPEN ACCESS nutrients ISSN 2072-6643 www.mdpi.com/journal/nutrients Review Gut Microbiota and Inflammation Asa Hakansson and Goran Molin * Food Hygiene, Division of Applied Nutrition, Department of Food Technology, Engineering and Nutrition, Lund University, PO Box 124, SE-22100 Lund, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-8327; Fax: +46-46-222-4532. Received: 15 April 2011; in revised form: 19 May 2011 / Accepted: 24 May 2011 / Published: 3 June 2011 Abstract: Systemic and local inflammation in relation to the resident microbiota of the human gastro-intestinal (GI) tract and administration of probiotics are the main themes of the present review. The dominating taxa of the human GI tract and their potential for aggravating or suppressing inflammation are described. The review focuses on human trials with probiotics and does not include in vitro studies and animal experimental models. The applications of probiotics considered are systemic immune-modulation, the metabolic syndrome, liver injury, inflammatory bowel disease, colorectal cancer and radiation-induced enteritis. When the major genomic differences between different types of probiotics are taken into account, it is to be expected that the human body can respond differently to the different species and strains of probiotics. This fact is often neglected in discussions of the outcome of clinical trials with probiotics. Keywords: probiotics; inflammation; gut microbiota 1. Inflammation Inflammation is a defence reaction of the body against injury. The word inflammation originates from the Latin word ―inflammatio‖ which means fire, and traditionally inflammation is characterised by redness, swelling, pain, heat and impaired body functions. -
The Isolation of Novel Lachnospiraceae Strains and the Evaluation of Their Potential Roles in Colonization Resistance Against Clostridium Difficile
The isolation of novel Lachnospiraceae strains and the evaluation of their potential roles in colonization resistance against Clostridium difficile Diane Yuan Wang Honors Thesis in Biology Department of Ecology and Evolutionary Biology College of Literature, Science, & the Arts University of Michigan, Ann Arbor April 1st, 2014 Sponsor: Vincent B. Young, M.D., Ph.D. Associate Professor of Internal Medicine Associate Professor of Microbiology and Immunology Medical School Co-Sponsor: Aaron A. King, Ph.D. Associate Professor of Ecology & Evolutionary Associate Professor of Mathematics College of Literature, Science, & the Arts Reader: Blaise R. Boles, Ph.D. Assistant Professor of Molecular, Cellular and Developmental Biology College of Literature, Science, & the Arts 1 Table of Contents Abstract 3 Introduction 4 Clostridium difficile 4 Colonization Resistance 5 Lachnospiraceae 6 Objectives 7 Materials & Methods 9 Sample Collection 9 Bacterial Isolation and Selective Growth Conditions 9 Design of Lachnospiraceae 16S rRNA-encoding gene primers 9 DNA extraction and 16S ribosomal rRNA-encoding gene sequencing 10 Phylogenetic analyses 11 Direct inhibition 11 Bile salt hydrolase (BSH) detection 12 PCR assay for bile acid 7α-dehydroxylase detection 12 Tables & Figures Table 1 13 Table 2 15 Table 3 21 Table 4 25 Figure 1 16 Figure 2 19 Figure 3 20 Figure 4 24 Figure 5 26 Results 14 Isolation of novel Lachnospiraceae strains 14 Direct inhibition 17 Bile acid physiology 22 Discussion 27 Acknowledgments 33 References 34 2 Abstract Background: Antibiotic disruption of the gastrointestinal tract’s indigenous microbiota can lead to one of the most common nosocomial infections, Clostridium difficile, which has an annual cost exceeding $4.8 billion dollars. -
Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms
nutrients Review Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms Annamaria Altomare 1,2 , Claudia Di Rosa 2,*, Elena Imperia 2, Sara Emerenziani 1, Michele Cicala 1 and Michele Pier Luca Guarino 1 1 Gastroenterology Unit, Campus Bio-Medico University of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy; [email protected] (A.A.); [email protected] (S.E.); [email protected] (M.C.); [email protected] (M.P.L.G.) 2 Unit of Food Science and Human Nutrition, Campus Bio-Medico University of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy; [email protected] * Correspondence: [email protected] Abstract: Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder charac- terized by abdominal pain associated with defecation or a change in bowel habits. Gut microbiota, which acts as a real organ with well-defined functions, is in a mutualistic relationship with the host, harvesting additional energy and nutrients from the diet and protecting the host from pathogens; specific alterations in its composition seem to play a crucial role in IBS pathophysiology. It is well known that diet can significantly modulate the intestinal microbiota profile but it is less known how different nutritional approach effective in IBS patients, such as the low-FODMAP diet, could be Citation: Altomare, A.; Di Rosa, C.; responsible of intestinal microbiota changes, thus influencing the presence of gastrointestinal (GI) Imperia, E.; Emerenziani, S.; Cicala, symptoms. The aim of this review was to explore the effects of different nutritional protocols (e.g., M.; Guarino, M.P.L. -
Product Sheet Info
Product Information Sheet for HM-300 Dorea formicigenerans, Strain Atmosphere: Anaerobic Propagation: 4_6_53AFAA 1. Keep vial frozen until ready for use, then thaw. 2. Transfer the entire thawed aliquot into a single tube of Catalog No. HM-300 broth. 3. Incubate the tube at 37°C for 1 to 2 days. For research use only. Not for human use. Citation: Contributor: Acknowledgment for publications should read “The following Emma Allen-Vercoe, Assistant Professor, Department of reagent was obtained through BEI Resources, NIAID, NIH as Molecular and Cellular Biology, University of Guelph, Guelph, part of the Human Microbiome Project: Dorea Ontario, Canada formicigenerans, Strain 4_6_53AFAA, HM-300.” Manufacturer: Biosafety Level: 1 BEI Resources Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following Product Description: publication: U.S. Department of Health and Human Services, Bacteria Classification: Lachnospiraceae, Dorea Public Health Service, Centers for Disease Control and Species: Dorea formicigenerans Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Strain: 4_6_53AFAA Washington, DC: U.S. Government Printing Office, 2009; see Original Source: Dorea formicigenerans (D. formicigenerans), www.cdc.gov/biosafety/publications/bmbl5/index.htm. strain 4_6_53AFAA was isolated from human gastrointestinal tract biopsy sample.1,2 Comments: D. formicigenerans, strain 4_6_53AFAA (HMP ID Disclaimers: 9457) is a reference genome for The Human Microbiome You are authorized to use this product for research use only. Project (HMP). HMP is an initiative to identify and It is not intended for human use. characterize human microbial flora. The complete genome of D. formicigenerans, strain 4_6_53AFAA was sequenced Use of this product is subject to the terms and conditions of at the Broad Institute (GenBank: ADLU00000000). -
Specific Substrate-Driven Changes in Human Faecal Microbiota Composition Contrast with Functional Redundancy in Short-Chain Fatty Acid Production
The ISME Journal (2018) 12, 610–622 © 2018 International Society for Microbial Ecology All rights reserved 1751-7362/18 www.nature.com/ismej ORIGINAL ARTICLE Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production Nicole Reichardt1,2, Maren Vollmer1, Grietje Holtrop3, Freda M Farquharson1, Daniel Wefers4, Mirko Bunzel4, Sylvia H Duncan1, Janice E Drew1, Lynda M Williams1, Graeme Milligan2, Thomas Preston5, Douglas Morrison5, Harry J Flint1 and Petra Louis1 1The Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen, UK; 2Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK; 3Biomathematics and Statistics Scotland, Foresterhill, Aberdeen, UK; 4Department of Food Chemistry and Phytochemistry, Karlsruhe Institute of Technology (KIT), Adenauerring 20A, Karlsruhe, Germany and 5Scottish Universities Environmental Research Centre, University of Glasgow, Rankine Avenue, East Kilbride, UK The diet provides carbohydrates that are non-digestible in the upper gut and are major carbon and energy sources for the microbial community in the lower intestine, supporting a complex metabolic network. Fermentation produces the short-chain fatty acids (SCFAs) acetate, propionate and butyrate, which have health-promoting effects for the human host. Here we investigated microbial community changes and SCFA production during in vitro batch incubations of 15 different non-digestible carbohydrates, at two initial pH values with faecal microbiota from three different human donors. To investigate temporal stability and reproducibility, a further experiment was performed 1 year later with four of the carbohydrates. The lower pH (5.5) led to higher butyrate and the higher pH (6.5) to more propionate production. -
Product Sheet Info
Product Information Sheet for HM-1038 Clostridium bolteae, Strain CC43_001B Growth Conditions: Media: Catalog No. HM-1038 Modified Reinforced Clostridial broth or Modified Chopped Meat medium or equivalent Tryptic Soy agar with 5% defibrinated sheep blood or For research use only. Not for human use. equivalent Incubation: Contributors: Temperature: 37°C Emma Allen-Vercoe, Assistant Professor, Department of Atmosphere: Anaerobic Molecular and Cellular Biology, University of Guelph, Guelph, Propagation: Ontario, Canada 1. Keep vial frozen until ready for use, then thaw. 2. Transfer the entire thawed aliquot into a single tube of Manufacturer: broth. BEI Resources 3. Use several drops of the suspension to inoculate an agar slant and/or plate. Product Description: 4. Incubate the tube, slant and/or plate at 37°C for 24 to Bacteria Classification: Clostridiaceae, Clostridium 48 hours. Species: Clostridium bolteae Strain: CC43_001B Citation: Original Source: Clostridium bolteae (C. bolteae), strain Acknowledgment for publications should read “The following CC43_001B was isolated in October 2010 from colonic reagent was obtained through BEI Resources, NIAID, NIH as biopsy tissue of a human subject in Victoria, British part of the Human Microbiome Project: Clostridium bolteae, Columbia, Canada.1 Strain CC43_001B, HM-1038.” Comments: C. bolteae, strain CC43_001B (HMP ID 1184) is a reference genome for The Human Microbiome Project Biosafety Level: 2 (HMP). HMP is an initiative to identify and characterize Appropriate safety procedures should always be used with human microbial flora. The complete genome of C. this material. Laboratory safety is discussed in the following bolteae, strain CC43_001B is currently being sequenced at publication: U.S. Department of Health and Human Services, the Broad Institute. -
BEI Resources Product Information Sheet Catalog No. HM-318
Product Information Sheet for HM-318 Clostridium bolteae, Strain WAL-14578 Growth Conditions: Media: Modified Chopped Meat Medium or equivalent Catalog No. HM-318 Tryptic Soy agar with 5% defibrinated sheep blood or equivalent For research use only. Not for use in humans. Incubation: Temperature: 37°C Contributor: Atmosphere: Anaerobic Emma Allen-Vercoe, Assistant Professor, Department of Propagation: Molecular and Cellular Biology, University of Guelph, Guelph, 1. Keep vial frozen until ready for use, then thaw. Ontario, Canada 2. Transfer the entire thawed aliquot into a single tube of broth. 3. Use several drops of the suspension to inoculate an agar Manufacturer: slant and/or plate. BEI Resources 4. Incubate the tube, slant and/or plate at 37°C for two to three days. Product Description: Bacteria Classification: Clostridiaceae, Clostridium Species: Clostridium bolteae Citation: Acknowledgment for publications should read “The following Strain: WAL-14578 (Wadsworth Anaerobe Laboratory) reagent was obtained through BEI Resources, NIAID, NIH as Original Source: Clostridium bolteae (C. bolteae), strain WAL- part of the Human Microbiome Project: Clostridium bolteae, 14578 was recovered from the stool of a male child with late- Strain WAL-14578, HM-318.” onset autism who had not received antimicrobial therapy.1,2 Comments: C. bolteae, strain WAL-14578 (HMP ID 9472) is a reference genome for The Human Microbiome Project Biosafety Level: 2 (HMP). HMP is an initiative to identify and characterize Appropriate safety procedures should always be used with this human microbial flora. The complete genome of C. bolteae material. Laboratory safety is discussed in the following WAL-14578 has been sequenced at the Broad Institute publication: U.S. -
Clostridium Pacaense: a New Species Within the Genus Clostridium
NEW SPECIES Clostridium pacaense: a new species within the genus Clostridium M. Hosny1, R. Abou Abdallah2, J. Bou Khalil1, A. Fontanini1, E. Baptiste1, N. Armstrong1 and B. La Scola1 1) Aix-Marseille Université UM63, Institut de Recherche pour le Développement IRD 198, Assistance Publique—Hôpitaux de Marseille (AP-HM), Microbes, Evolution, Phylogeny and Infection (MEΦI), Institut Hospitalo-Universitaire (IHU)-Méditerranée Infection and 2) Aix-Marseille Université UM63, Institut de Recherche pour le Développement IRD 198, Assistance Publique—Hôpitaux de Marseille (AP-HM), Vecteurs—Infections Tropicales et Méditerrannéennes (VITROME), Service de Santé des Armées, IHU-Méditerranée Infection, Marseille, France Abstract Using the strategy of taxonogenomics, we described Clostridium pacaense sp. nov. strain Marseille-P3100T, a Gram-variable, nonmotile, spore- forming anaerobic bacillus. This strain was isolated from a 3.3-month-old Senegalese girl with clinical aspects of marasmus. The closest species based on 16S ribosomal RNA was Clostridium aldenense, with a similarity of 98.4%. The genome length was 2 672 129 bp, with a 50% GC content; 2360 proteins were predicted. Finally, predominant fatty acids were hexadecanoic acid, tetradecanoic acid and 9-hexadecenoic acid. © 2019 The Authors. Published by Elsevier Ltd. Keywords: Clostridium pacaense, culturomics, taxonogenomics Original Submission: 16 October 2018; Revised Submission: 21 December 2018; Accepted: 21 December 2018 Article published online: 31 December 2018 mammalian gastrointestinal tract microbiomes [7]. Culturomics Corresponding author: B. La Scola, Pôle des Maladies Infectieuses, combined with taxonogenomics is an important tool for the Aix-Marseille Université, IRD, Assistance Publique—Hôpitaux de Marseille (AP-HM), Microbes, Evolution, Phylogeny and Infection isolation and characterization of new bacterial species. -
Outline Release 7 7C
Garrity, et. al., March 6, 2007 Taxonomic Outline of the Bacteria and Archaea, Release 7.7 March 6, 2007. Part 7 – The Bacteria: Phylum “Firmicutes”: Class “Clostridia” George M. Garrity, Timothy G. Lilburn, James R. Cole, Scott H. Harrison, Jean Euzéby, and Brian J. Tindall F Phylum Firmicutes AL N4Lid DOI: 10.1601/nm.3874 Class "Clostridia" N4Lid DOI: 10.1601/nm.3875 71 Order Clostridiales AL Prévot 1953. N4Lid DOI: 10.1601/nm.3876 Family Clostridiaceae AL Pribram 1933. N4Lid DOI: 10.1601/nm.3877 Genus Clostridium AL Prazmowski 1880. GOLD ID: Gi00163. GCAT ID: 000971_GCAT. Entrez genome id: 80. Sequenced strain: BC1 is from a non-type strain. Genome sequencing is incomplete. Number of genomes of this species sequenced 6 (GOLD) 6 (NCBI). N4Lid DOI: 10.1601/nm.3878 Clostridium butyricum AL Prazmowski 1880. Source of type material recommended for DOE sponsored genome sequencing by the JGI: ATCC 19398. High-quality 16S rRNA sequence S000436450 (RDP), M59085 (Genbank). N4Lid DOI: 10.1601/nm.3879 Clostridium aceticum VP (ex Wieringa 1940) Gottschalk and Braun 1981. Source of type material recommended for DOE sponsored genome sequencing by the JGI: ATCC 35044. High-quality 16S rRNA sequence S000016027 (RDP), Y18183 (Genbank). N4Lid DOI: 10.1601/nm.3881 Clostridium acetireducens VP Örlygsson et al. 1996. Source of type material recommended for DOE sponsored genome sequencing by the JGI: DSM 10703. High-quality 16S rRNA sequence S000004716 (RDP), X79862 (Genbank). N4Lid DOI: 10.1601/nm.3882 Clostridium acetobutylicum AL McCoy et al. 1926. Source of type material recommended for DOE sponsored genome sequencing by the JGI: ATCC 824. -
Harvesting of Prebiotic Fructooligosaccharides by Nonbeneficial Human Gut Bacteria Zhi Wang, Alexandra S
Harvesting of Prebiotic Fructooligosaccharides by Nonbeneficial Human Gut Bacteria Zhi Wang, Alexandra S. Tauzin, Elisabeth Laville, Pietro Tedesco, Fabien Letisse, Nicolas Terrapon, Pascale Lepercq, Myriam Mercade, Gabrielle Potocki-Veronese To cite this version: Zhi Wang, Alexandra S. Tauzin, Elisabeth Laville, Pietro Tedesco, Fabien Letisse, et al.. Harvesting of Prebiotic Fructooligosaccharides by Nonbeneficial Human Gut Bacteria. mSphere, 2020, 5 (1), 26 p. 10.1128/mSphere.00771-19. hal-02478442 HAL Id: hal-02478442 https://hal.archives-ouvertes.fr/hal-02478442 Submitted on 13 Feb 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License RESEARCH ARTICLE Molecular Biology and Physiology Harvesting of Prebiotic Fructooligosaccharides by Nonbeneficial Human Gut Bacteria a a a a a b,c a Zhi Wang, Alexandra S. Tauzin, Elisabeth Laville, Pietro Tedesco, Fabien Létisse, Nicolas Terrapon, Pascale Lepercq, Downloaded from Myriam Mercade,a Gabrielle Potocki-Veronesea aTBI, CNRS, INRA, INSAT, Université de Toulouse, Toulouse, France bAFMB, UMR 7257 CNRS, Aix-Marseille Université, Marseille, France cINRA, USC 1408 AFMB, Marseille, France ABSTRACT Prebiotic oligosaccharides, such as fructooligosaccharides, are increas- ingly being used to modulate the composition and activity of the gut microbiota. -
Rebuilding the Gut Microbiota Ecosystem
International Journal of Environmental Research and Public Health Review Rebuilding the Gut Microbiota Ecosystem Antonella Gagliardi, Valentina Totino, Fatima Cacciotti, Valerio Iebba, Bruna Neroni, Giulia Bonfiglio, Maria Trancassini, Claudio Passariello ID , Fabrizio Pantanella and Serena Schippa * Department of Public Health and Infectious Diseases, Section of Microbiology, Sapienza University of Rome, Rome 00185, Italy; [email protected] (A.G.); [email protected] (V.T.); [email protected] (F.C.); [email protected] (V.I.); [email protected] (B.N.); giulia.bonfi[email protected] (G.B.); [email protected] (M.T.); [email protected] (C.P.); [email protected] (F.P.) * Correspondence: [email protected]; Tel.: +39-339-115-2753 Received: 19 June 2018; Accepted: 4 August 2018; Published: 7 August 2018 Abstract: A microbial ecosystem in which bacteria no longer live in a mutualistic association is called dysbiotic. Gut microbiota dysbiosis is a condition related with the pathogenesis of intestinal illnesses (irritable bowel syndrome, celiac disease, and inflammatory bowel disease) and extra-intestinal illnesses (obesity, metabolic disorder, cardiovascular syndrome, allergy, and asthma). Dysbiosis status has been related to various important pathologies, and many therapeutic strategies aimed at restoring the balance of the intestinal ecosystem have been implemented. These strategies include the administration of probiotics, prebiotics, and synbiotics; phage therapy; fecal transplantation; bacterial consortium transplantation; and a still poorly investigated approach based on predatory bacteria. This review discusses the various aspects of these strategies to counteract intestinal dysbiosis. Keywords: gut microbiota; eubiosis; dysbiosis; therapeutic strategy 1. Introduction Bacteria (bacteriome), fungi (mycome) [1], and viruses (virome) [2] live together in a harmonic and dynamic equilibrium in the intestinal tract.